This post was originally published on this site
Pfizer’s PFE proposed acquisition of Seagen SGEN, which develops cancer treatments, for $43 billion indicates that the legacy drugmaker is focused on shoring up its oncology business.
Pfizer said Monday it plans to pay $229 per share in cash for Seagen, whose stock soared more than 15% in trading on Monday afternoon. Pfizer’s shares gained about 1.7%.
“[Seagen’s]…
